ReviewFrontiers in immunology2026
miRNAs bridging the gap between the tumor microenvironment and liquid biopsy in cutaneous melanoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma remains one of the most challenging neoplasms and the deadliest form of skin cancer. miRNAs are a class of non-coding RNA molecules found in both tissues and body fluids that can negatively regulate gene expression in eukaryotic cells, playing key roles in health and disease. Dysregulated miRNA levels have been linked to various aspects of melanocytic tumor biology, including the transition from benign to malignant stages, immunosuppression, dissemination, and therapy resistance. Here, we provide a timely review of the roles of miRNAs within the cutaneous melanoma tumor microenvironment, emphasizing their impact on immune cell phenotypes and functions, angiogenesis, innate and adaptive immunity, and immune checkpoint expression to help refine future biomarkers and therapeutic targets in the field. We will also address their roles in circular and long non-coding RNA sponging interactions and the potential for translating miRNAs into clinical practice, given their simultaneous presence in both cutaneous melanoma tissues and liquid biopsies. The main challenges and limitations associated with such a translational approach will also be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.